Concerns Arise Over Long-Term Safety of ADHD Medication in Children

Recent research conducted by the University of Turku, University of Helsinki, and the Finnish Social Insurance Institution Kela highlights growing concerns about the prolonged use of ADHD medications among children and adolescents. The study shows that the average duration of medication treatment exceeds three years, with some children remaining on these medications for over seven years. Despite widespread use, reliable data on the safety of these medications during extended use are limited to short-term follow-up periods of about one year.

ADHD medication usage has increased significantly in recent years, especially in Finland, where the prevalence continues to grow. The study found that boys are treated more frequently and for longer durations than girls, particularly those who begin medication between ages 6 and 8. The median treatment period for boys starting at this age was around 6.3 years, with a quarter of them on medication for more than 9.4 years.

Lead researcher Päivi Ruokoniemi expressed concern over the long-term use of these drugs, emphasizing that children at critical developmental stages are particularly vulnerable. She noted that current safety data is insufficient, as clinical trials typically only monitor patients for up to one year, whereas real-world treatment often lasts much longer.

The researchers highlight the need for more comprehensive, long-term studies to better understand the potential consequences of prolonged medication use in children. They stress that pharmacological treatment should only be initiated after unsuccessful non-drug interventions and that ongoing review by medical professionals is essential.

This study underscores the importance of cautious prescribing and close monitoring of children on ADHD medications, considering their ongoing development and the current gaps in safety data. The findings were published in the journal European Child & Adolescent Psychiatry and are part of a broader effort to ensure the well-being of young patients receiving these treatments.